[1]Elliott PM, Anastasakis A, Borger MA,et al.[2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy][J]. Kardiol Pol,2014,72(11): 1054-1126.[2] Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA Guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology. Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons[J]. J Am Coll Cardiol,2011,58(25): e212-e260.[3] Durand E, Mousseaux E, Coste P, et al. Nonsurgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy: early and 6 months followup[J]. Eur Heart J, 2008, 29(3): 348-355.[4] O′Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM riskSCD)[J]. Eur Heart J, 2014, 35(30): 2010-2020.